IBDEI0Q4 ; ; 01-FEB-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,11739,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11739,1,3,0)
;;=3^Chr nephritic syndrome w/ diffuse endocaplry prolif glomrlneph
;;^UTILITY(U,$J,358.3,11739,1,4,0)
;;=4^N03.4
;;^UTILITY(U,$J,358.3,11739,2)
;;=^5015525
;;^UTILITY(U,$J,358.3,11740,0)
;;=N03.5^^46^573^16
;;^UTILITY(U,$J,358.3,11740,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11740,1,3,0)
;;=3^Chr nephritic syndrome w/ diffuse mesangiocap glomrlneph
;;^UTILITY(U,$J,358.3,11740,1,4,0)
;;=4^N03.5
;;^UTILITY(U,$J,358.3,11740,2)
;;=^5015526
;;^UTILITY(U,$J,358.3,11741,0)
;;=N03.6^^46^573^11
;;^UTILITY(U,$J,358.3,11741,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11741,1,3,0)
;;=3^Chr nephritic syndrome w/ dense deposit disease
;;^UTILITY(U,$J,358.3,11741,1,4,0)
;;=4^N03.6
;;^UTILITY(U,$J,358.3,11741,2)
;;=^5015527
;;^UTILITY(U,$J,358.3,11742,0)
;;=N03.7^^46^573^12
;;^UTILITY(U,$J,358.3,11742,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11742,1,3,0)
;;=3^Chr nephritic syndrome w/ diffuse crescentic glomrlneph
;;^UTILITY(U,$J,358.3,11742,1,4,0)
;;=4^N03.7
;;^UTILITY(U,$J,358.3,11742,2)
;;=^5015528
;;^UTILITY(U,$J,358.3,11743,0)
;;=N03.8^^46^573^19
;;^UTILITY(U,$J,358.3,11743,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11743,1,3,0)
;;=3^Chr nephritic syndrome w/ other morphologic changes
;;^UTILITY(U,$J,358.3,11743,1,4,0)
;;=4^N03.8
;;^UTILITY(U,$J,358.3,11743,2)
;;=^5015529
;;^UTILITY(U,$J,358.3,11744,0)
;;=N03.9^^46^573^20
;;^UTILITY(U,$J,358.3,11744,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11744,1,3,0)
;;=3^Chr nephritic syndrome w/ unsp morphologic changes
;;^UTILITY(U,$J,358.3,11744,1,4,0)
;;=4^N03.9
;;^UTILITY(U,$J,358.3,11744,2)
;;=^5015530
;;^UTILITY(U,$J,358.3,11745,0)
;;=N04.0^^46^573^59
;;^UTILITY(U,$J,358.3,11745,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11745,1,3,0)
;;=3^Nephrotic syndrome w/ minor glomerular abnormality
;;^UTILITY(U,$J,358.3,11745,1,4,0)
;;=4^N04.0
;;^UTILITY(U,$J,358.3,11745,2)
;;=^5015531
;;^UTILITY(U,$J,358.3,11746,0)
;;=N04.1^^46^573^58
;;^UTILITY(U,$J,358.3,11746,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11746,1,3,0)
;;=3^Nephrotic syndrome w/ focal & segmental glomerular lesions
;;^UTILITY(U,$J,358.3,11746,1,4,0)
;;=4^N04.1
;;^UTILITY(U,$J,358.3,11746,2)
;;=^5015532
;;^UTILITY(U,$J,358.3,11747,0)
;;=N04.2^^46^573^55
;;^UTILITY(U,$J,358.3,11747,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11747,1,3,0)
;;=3^Nephrotic syndrome w/ diffuse membranous glomerulonephritis
;;^UTILITY(U,$J,358.3,11747,1,4,0)
;;=4^N04.2
;;^UTILITY(U,$J,358.3,11747,2)
;;=^5015533
;;^UTILITY(U,$J,358.3,11748,0)
;;=N04.3^^46^573^56
;;^UTILITY(U,$J,358.3,11748,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11748,1,3,0)
;;=3^Nephrotic syndrome w/ diffuse mesangial prolif glomrlneph
;;^UTILITY(U,$J,358.3,11748,1,4,0)
;;=4^N04.3
;;^UTILITY(U,$J,358.3,11748,2)
;;=^5015534
;;^UTILITY(U,$J,358.3,11749,0)
;;=N04.4^^46^573^54
;;^UTILITY(U,$J,358.3,11749,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11749,1,3,0)
;;=3^Nephrotic syndrome w/ diffuse endocaplry prolif glomrlneph
;;^UTILITY(U,$J,358.3,11749,1,4,0)
;;=4^N04.4
;;^UTILITY(U,$J,358.3,11749,2)
;;=^5015535
;;^UTILITY(U,$J,358.3,11750,0)
;;=N04.5^^46^573^57
;;^UTILITY(U,$J,358.3,11750,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,11750,1,3,0)
;;=3^Nephrotic syndrome w/ diffuse mesangiocapillary glomrlneph
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI0Q4 3777 printed Nov 22, 2024@17:03:47 Page 2
IBDEI0Q4 ; ; 01-FEB-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,11739,1,0)
+2 ;;=^358.31IA^4^2
+3 ;;^UTILITY(U,$J,358.3,11739,1,3,0)
+4 ;;=3^Chr nephritic syndrome w/ diffuse endocaplry prolif glomrlneph
+5 ;;^UTILITY(U,$J,358.3,11739,1,4,0)
+6 ;;=4^N03.4
+7 ;;^UTILITY(U,$J,358.3,11739,2)
+8 ;;=^5015525
+9 ;;^UTILITY(U,$J,358.3,11740,0)
+10 ;;=N03.5^^46^573^16
+11 ;;^UTILITY(U,$J,358.3,11740,1,0)
+12 ;;=^358.31IA^4^2
+13 ;;^UTILITY(U,$J,358.3,11740,1,3,0)
+14 ;;=3^Chr nephritic syndrome w/ diffuse mesangiocap glomrlneph
+15 ;;^UTILITY(U,$J,358.3,11740,1,4,0)
+16 ;;=4^N03.5
+17 ;;^UTILITY(U,$J,358.3,11740,2)
+18 ;;=^5015526
+19 ;;^UTILITY(U,$J,358.3,11741,0)
+20 ;;=N03.6^^46^573^11
+21 ;;^UTILITY(U,$J,358.3,11741,1,0)
+22 ;;=^358.31IA^4^2
+23 ;;^UTILITY(U,$J,358.3,11741,1,3,0)
+24 ;;=3^Chr nephritic syndrome w/ dense deposit disease
+25 ;;^UTILITY(U,$J,358.3,11741,1,4,0)
+26 ;;=4^N03.6
+27 ;;^UTILITY(U,$J,358.3,11741,2)
+28 ;;=^5015527
+29 ;;^UTILITY(U,$J,358.3,11742,0)
+30 ;;=N03.7^^46^573^12
+31 ;;^UTILITY(U,$J,358.3,11742,1,0)
+32 ;;=^358.31IA^4^2
+33 ;;^UTILITY(U,$J,358.3,11742,1,3,0)
+34 ;;=3^Chr nephritic syndrome w/ diffuse crescentic glomrlneph
+35 ;;^UTILITY(U,$J,358.3,11742,1,4,0)
+36 ;;=4^N03.7
+37 ;;^UTILITY(U,$J,358.3,11742,2)
+38 ;;=^5015528
+39 ;;^UTILITY(U,$J,358.3,11743,0)
+40 ;;=N03.8^^46^573^19
+41 ;;^UTILITY(U,$J,358.3,11743,1,0)
+42 ;;=^358.31IA^4^2
+43 ;;^UTILITY(U,$J,358.3,11743,1,3,0)
+44 ;;=3^Chr nephritic syndrome w/ other morphologic changes
+45 ;;^UTILITY(U,$J,358.3,11743,1,4,0)
+46 ;;=4^N03.8
+47 ;;^UTILITY(U,$J,358.3,11743,2)
+48 ;;=^5015529
+49 ;;^UTILITY(U,$J,358.3,11744,0)
+50 ;;=N03.9^^46^573^20
+51 ;;^UTILITY(U,$J,358.3,11744,1,0)
+52 ;;=^358.31IA^4^2
+53 ;;^UTILITY(U,$J,358.3,11744,1,3,0)
+54 ;;=3^Chr nephritic syndrome w/ unsp morphologic changes
+55 ;;^UTILITY(U,$J,358.3,11744,1,4,0)
+56 ;;=4^N03.9
+57 ;;^UTILITY(U,$J,358.3,11744,2)
+58 ;;=^5015530
+59 ;;^UTILITY(U,$J,358.3,11745,0)
+60 ;;=N04.0^^46^573^59
+61 ;;^UTILITY(U,$J,358.3,11745,1,0)
+62 ;;=^358.31IA^4^2
+63 ;;^UTILITY(U,$J,358.3,11745,1,3,0)
+64 ;;=3^Nephrotic syndrome w/ minor glomerular abnormality
+65 ;;^UTILITY(U,$J,358.3,11745,1,4,0)
+66 ;;=4^N04.0
+67 ;;^UTILITY(U,$J,358.3,11745,2)
+68 ;;=^5015531
+69 ;;^UTILITY(U,$J,358.3,11746,0)
+70 ;;=N04.1^^46^573^58
+71 ;;^UTILITY(U,$J,358.3,11746,1,0)
+72 ;;=^358.31IA^4^2
+73 ;;^UTILITY(U,$J,358.3,11746,1,3,0)
+74 ;;=3^Nephrotic syndrome w/ focal & segmental glomerular lesions
+75 ;;^UTILITY(U,$J,358.3,11746,1,4,0)
+76 ;;=4^N04.1
+77 ;;^UTILITY(U,$J,358.3,11746,2)
+78 ;;=^5015532
+79 ;;^UTILITY(U,$J,358.3,11747,0)
+80 ;;=N04.2^^46^573^55
+81 ;;^UTILITY(U,$J,358.3,11747,1,0)
+82 ;;=^358.31IA^4^2
+83 ;;^UTILITY(U,$J,358.3,11747,1,3,0)
+84 ;;=3^Nephrotic syndrome w/ diffuse membranous glomerulonephritis
+85 ;;^UTILITY(U,$J,358.3,11747,1,4,0)
+86 ;;=4^N04.2
+87 ;;^UTILITY(U,$J,358.3,11747,2)
+88 ;;=^5015533
+89 ;;^UTILITY(U,$J,358.3,11748,0)
+90 ;;=N04.3^^46^573^56
+91 ;;^UTILITY(U,$J,358.3,11748,1,0)
+92 ;;=^358.31IA^4^2
+93 ;;^UTILITY(U,$J,358.3,11748,1,3,0)
+94 ;;=3^Nephrotic syndrome w/ diffuse mesangial prolif glomrlneph
+95 ;;^UTILITY(U,$J,358.3,11748,1,4,0)
+96 ;;=4^N04.3
+97 ;;^UTILITY(U,$J,358.3,11748,2)
+98 ;;=^5015534
+99 ;;^UTILITY(U,$J,358.3,11749,0)
+100 ;;=N04.4^^46^573^54
+101 ;;^UTILITY(U,$J,358.3,11749,1,0)
+102 ;;=^358.31IA^4^2
+103 ;;^UTILITY(U,$J,358.3,11749,1,3,0)
+104 ;;=3^Nephrotic syndrome w/ diffuse endocaplry prolif glomrlneph
+105 ;;^UTILITY(U,$J,358.3,11749,1,4,0)
+106 ;;=4^N04.4
+107 ;;^UTILITY(U,$J,358.3,11749,2)
+108 ;;=^5015535
+109 ;;^UTILITY(U,$J,358.3,11750,0)
+110 ;;=N04.5^^46^573^57
+111 ;;^UTILITY(U,$J,358.3,11750,1,0)
+112 ;;=^358.31IA^4^2
+113 ;;^UTILITY(U,$J,358.3,11750,1,3,0)
+114 ;;=3^Nephrotic syndrome w/ diffuse mesangiocapillary glomrlneph
